Welcome 2018!
We wish all our readers happy holidays and will be back in the new year with more news and updates on rare diseases!
//= $linkOg ?>
We wish all our readers happy holidays and will be back in the new year with more news and updates on rare diseases!
RD-ACTION, the European Joint Action for Rare Diseases, has dedicated considerable energies and resources to support the implementation and development of European Reference Networks (ERNs), particularly through its Policy and Integration Work Package. The reason for this focus is simple: ERNs offer an unprecedented opportunity for the rare disease and specialised healthcare communities in Europe by concentrating expertise and resources across the many thousands of rare conditions, bringing patients a step closer to real equality in accessing the best possible care regardless of where they happen to live. The responsibilities of ERNs are numerous and daunting: therefore, RD-ACTION set-out to add value by working with the new Networks to identify -and where possible, support the embedding of- good practices and resources, by drawing upon successes in the rare disease and rare cancer field in the pre-ERN era as well as cutting-edge developments in broader fields, and seeking to translate these to the Networks.
An important step in this mission occurred earlier this month in Rome, in the form of a major workshop uniting key stakeholders to explore for the first time exactly how and where the ERNs can add value to the essential functions of generating, appraising, disseminating and using Clinical Practice Guidelines (CPGs).
Why Clinical Practice Guidelines? As ERNs are first and foremost about care (albeit with a strong research bent), a vital duty is the requirement to ‘develop and use clinical practice guidelines’ as emphasized in the Legal acts upon which the ERNs are based. Clinical practice guidelines can serve as a great equaliser in the RD field: they can mean the difference between no care/substandard care and patients living longer, healthier lives with fewer complications. Guidelines, whether designed to support diagnosis, treatment or care, can serve as a blueprint of excellence, to advise doctors closer to the patients on how to treat them in a way that reflects the best possible knowledge and will generate the best possible outcomes.
For these reasons, the CPG topic was chosen as the focus of the latest major workshop organised by RD-ACTION and DG-SANTE. The workshop took place in Rome, on 6th and 7th December, and organisation was a multi-stakeholder effort (WP6 partners UNEW and EURORDIS, DG SANTE, the ERN Coordinator Group Chair, and the coordinators of the Joint Actions for rare diseases and for rare cancers). RD-ACTION Partners Istituto Superiore di Sanità hosted the event.
The workshop united 63 participants, the majority of whom were nominated by the ERNs themselves (23 of the 24 ERNs were represented) -this was in recognition of the fact that, within the ERNs -which are typically composed of several previously-isolated clinical domains- there is a wealth of expertise (often facilitated through past European Commission (EC) projects). In addition, several projects/initiatives have received EC funding to address this issue and it was felt that the fruits of such investment and expertise should be considered in the light of the ERN mission, to help the Networks understand and gauge the applicability of existing cross-cutting (disease-agnostic) tools; therefore, presentations were organised to illustrate the resources resulting from Rare-BestPractices and Orphanet. The approach of the rare cancer community (i.e. the JARC) was also considered. However, the plans and priorities of the ERNs themselves were at the heart of the workshop: a survey had been conducted, to gather preliminary information on these plans, and five quite different Networks presented detailed cases studies on their activities.
A key goal of the workshop was the identification of good practices which could be shaped into ‘recommendations’ (similar to the recent ‘Recommended Practices for Data Standardisation in the Context of the operation of ERNs’ designed to reflect the feel of EUCERD & CEGRD Guidance) concerning several aspects of this vast and complex topic. To achieve this goal, there was a particular emphasis on discussion and plenty of time for debate. The main ‘areas’ highlighted for recommendations include the following:
The outputs of the workshops and next steps will be available in the New Year, through the dedicated webpage (which already hosts the agenda, participants list, executive summary and presentations).
The theme of the International Rare Disease Day 2018, organised by EURORDIS, will be once more “research”, with a particular focus on the role of rare disease patients in this field. This highly successful and influential initiative will this year highlight rare disease (RD) patients’ contribution to research projects (fundraising), clinical trial design, the establishment of networks and data sharing between patient organisations.
Everyone is welcome to participate this year by uploading a picture representing the Rare Disease Day logo, by telling their story and sharing their experience on the rarediseaseday.org website, where visitors can find more possible ways to be part of the adventure.